ORG-26576

ORG-26576 is an ampakine originally developed by Cortex Pharmaceuticals and then licensed to Organon International for development. In animal studies it has been shown to effectively potentiate AMPA receptor function, leading to increased BDNF release and enhanced neuronal differentiation and survival, as well as producing nootropic effects in standardised assays.^{[1][2][3][4][5][6]} Development as an antidepressant has been halted due to a failed Phase II trial for major depressive disorder.^[7]

ORG-26576

Identifiers
IUPAC name (9aS)-8,9,9a,10-Tetrahydro-5H,7H-pyrido[3,2-f]pyrrolo[2,1-c][1,4]oxazepin-5-one
CAS Number	1026791-61-6
PubChem CID	13584912
ChemSpider	32697513
UNII	0H1IDR8Z4F
CompTox Dashboard (EPA)	DTXSID001336129
Chemical and physical data
Formula	C11H12N2O2
Molar mass	204.229 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1C[C@H]2COC3=C(C=CC=N3)C(=O)N2C1
InChI InChI=1S/C11H12N2O2/c14-11-9-4-1-5-12-10(9)15-7-8-3-2-6-13(8)11/h1,4-5,8H,2-3,6-7H2/t8-/m0/s1 Key:FIKUEZUFASUKAH-QMMMGPOBSA-N

See also

• AMPA receptor positive allosteric modulator